Ontario Institute invests in a radiolabeled insulin probe
The Ontario Institute for Cancer Research (OICR) in Toronto has invested $415,000 towards the development of a radiolabeled insulin probe for the early detection of breast cancer.
The recipient of the award is John Valliant, PhD, acting director of the McMaster Institute of applied radiation sciences in Ontario, Canada, who has developed a form of insulin that is labeled with technetium.
OICR said it will actively participate in efforts to commercialize the project by providing additional expertise and resources and working collaboratively with McMaster University and Valliant.
The recipient of the award is John Valliant, PhD, acting director of the McMaster Institute of applied radiation sciences in Ontario, Canada, who has developed a form of insulin that is labeled with technetium.
OICR said it will actively participate in efforts to commercialize the project by providing additional expertise and resources and working collaboratively with McMaster University and Valliant.